CSF2 and COVID-19: Antibodies targeting IL-6 or GM-CSF, such as tocilizumab, sarilumab, gimsilumab, and lenzilumab, are approved or under clinical investigations to treat severe COVID-19 patients (Agrawal et al., 2021; D’Alessio et al., 2021).